EUCTR2007-004138-17-ES进行中（未招募）1 期
Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída.Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 466
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years
- •2. KPS performance status = 70%
- •3. All patients must have documented evidence of multiple myeloma. All patients must have documented progression of disease after initial response to one line of therapy (either relapse from CR or progressive disease by EBMT/IBMTR criteria; see Section 5.3.1). Patients who proceeded to high-dose chemotherapy followed by stem cell transplantation (autologous or allogeneic; myeloablative or non-myeloablative; single or tandem) without documented progressive disease prior to SCT remain eligible for this protocol. Patients who received maintenance therapy following the SCT also remain eligible for this protocol, provided progression by EBMT/IBMTR criteria was not observed between SCT and initiation of maintenance
- •therapy. If the patient begins a second antimyeloma agent (for example, dexamethasone) without documented prior progression on the single-agent therapy, this will count as one regimen
- •4. All patients must have measurable disease (serum M-protein > 0.5 g/dL or > 200 mg urinary M-protein excretion/24-hour). (Patients who meet these criteria for measurable disease must also meet requirement for documentation of progressive disease by EBMT criteria). Patients with non-secretory or oligosecretory
- •disease are not eligible for the study. Disease must be assessed within 14 days prior to randomization
- •5. For those patients who received prior bortezomib or a bortezomib-containing regimen: patients must have achieved a CR or PR by EBMT/IBMTR criteria. Patients may not have received a bortezomib-containing regimen following SCT as
- •maintenance therapy
- •6. All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to NCI CTCAE (v. 3.0) Grade = 2 (except for neuropathy and diarrhea which must be Grade = 1 and painful neuropathy which must have resolved)
- •7. The following laboratory results, within 14 days of randomization:
- •Hemoglobin = 7.5 g/dL (if transfused within 14 days of randomization, pre- transfusion hemoglobin = 7 g/dL)
- •Absolute neutrophils count = 0.750 x 10 to the 9/L (with or without growth factor support within 14 days of randomization)
- •Platelet count = 50 x 10 to the 9/L (without platelet transfusions within 14 days prior to randomization; if transfused within 14 days of randomization, pre-transfusion platelet count must be = 50 x 10 to the 9/L)
- •Total bilirubin = 2 x ULN
- •AST = 2.5 x ULN
- •Serum creatinine = 2 x ULN or = 20 mL/min CrCL
- •Pregnancy test (serum or urine): negative (in all women of child-bearing potential)
- •8. Signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically sterile or they must agree to use a physical method of contraception or agree to complete sexual abstinence throughout her participation on trial. Female patients with childbearing potential must have a negative pregnancy test within 14 days prior to randomization. Male patients must be surgically sterile or agree to use an acceptable method of contraception, including abstinence
- •2. Administration of chemotherapy, biological, immunotherapy or investigational agent (therapeutic or diagnostic) within 21 days prior to randomization (14 days for non-myelosuppressive therapy in which drug-related toxicities have resolved per
- •Inclusion Criterion #6). Patients should be 6 weeks from last dose of nitrosourea or monoclonal antibody, 10 weeks from autologous SCT, and 16 weeks from allogeneic SCT
- •3. For patients who have received prior allogeneic SCT: patients with moderate-to-severe chronic graft versus host disease (GvHD) as defined in Filipovich et al 2005
- •4. Treatment with plasmapheresis within 30 days prior to randomization
- •5. Prior therapy with a heat shock protein 90 inhibitor or an investigational proteasome inhibitor
- •6. Concurrent use of corticosteroids other than low dose oral prednisone of 5 mg qd or less (or its equivalent); inhaled corticosteroids for the treatment of pulmonary disease that result in little-to-no systemic absorption are permitted. Patients
- •currently receiving corticosteroids at a higher dose must have corticosteroids safely tapered to this level at least 7 days prior to randomization to be eligible
- •7. Grade 3 dyspnea (dyspnea with activities of daily living) or a requirement for supplemental oxygen
- •8. Known or suspected cardiac amyloidosis; POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes), or plasma cell leukemia (defined as either 20% of peripheral WBC
- •comprised of CD138+ cells or an absolute count of 2 x 10 to the 9 /L)
- •9. Known hepatitis A, B or C viral infection; HIV infection
- •10. Any medical conditions that, in the Investigator’s opinion, would impose excessive risk to the patient. Examples of such conditions include congestive heart failure of Class III or IV of the NYHA classification, infection requiring parenteral antiinfective treatment, any altered mental status or any psychiatric condition that would interfere with the understanding of the informed consent
研究者
相似试验
进行中（未招募）
1 期
Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica.A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic MalignancyEUCTR2010-023156-89-ESMerck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc5,136
进行中（未招募）
不适用
Estudio clínico en fase 3, aleatorizado, controlado, doble ciego y multinacional sobre la eficacia y seguridad de vosaroxina y citarabina frente a placebo y citarabina en pacientes con leucemia mieloide aguda recurrente o en primera recaída. (Estudio VALOR) - VALOREUCTR2010-021961-61-ESSunesis Pharmaceuticals, Inc.750
进行中（未招募）
1 期
Ensayo clínico de fase III aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de la adición de sitagliptina (MK-0431) en pacientes con diabetes mellitus de tipo 2 que presentan un control insuficiente de la glucemia con un tratamiento combinado con metformina y pioglitazona. A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and PioglitazoneDiabetes Mellitus tipo 2 Type 2 diabetes mellitusMedDRA version: 9.1 Level: LLT Classification code 10053247 Term: Insulin-requiring type 2 diabetes mellitusEUCTR2008-006720-62-ESMerck & Co., Inc.266
进行中（未招募）
不适用
Estudio clínico en fase III, aleatorizado y doble ciego de 6 meses de duración para comparar la eficacia y la seguridad del colirio de combinación de dosis fijas de tafluprost al 0,0015% y timolol al 0,5% sin conservantes con las de los colirios de tafluprost al 0,0015% y timolol al 0,5% administrados simultáneamente en pacientes con glaucoma de ángulo abierto o hipertensión ocular.A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to those of tafluprost 0.0015% and timolol 0.5% eye drops given concomitantly in patients with open angle glaucoma or ocular hypertension. - Estudio de no inferioridad de combinación de dosis fija de tafluprost-timolol comparado con administPacientes con diagnóstico de hipertensión ocular o glaucoma de ángulo abierto (glaucoma primario de ángulo abierto, glaucoma capsular o glaucoma pigmentario).Patients diagnosed with ocular hypertension or open-angle glaucoma (primary open-angle glaucoma [POAG], capsular glaucoma or pigmentary glaucoma).MedDRA version: 12.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 12.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaMedDRA version: 12.1Level: LLTClassification code 10035015Term: Pigmentary glaucomaMedDRA version: 12.1Level: LLTClassification code 10037118Term: Pseudoexfoliation glaucomaEUCTR2010-022984-36-ESSanten Oy380
进行中（未招募）
不适用
Ensayo clínico de fase III con retirada aleatorizada, multicéntrico, doble ciego, controlado con placebo y con tratamiento activo, para evaluar la seguridad y la eficacia de CG5503 LP* por vía oral en pacientes con dolor tumoral crónico moderado o severo. - n.a.Dolor tumoral crónico de moderado a severo.MedDRA version: 8.1Level: LLTClassification code 10058019Term: Cancer painEUCTR2006-004997-28-ESaboratorios Andrómaco, S.A. (compañía perteneciente al Grupo Grünenthal España)573